ObsEva is developing a novel generation of drugs addressing serious conditions affecting women’s reproductive health and compromising pregnancy from conception to birth
Our management & collaborators combine successful experiences and track records in managing drug development and business development in large pharma & biotech companies.
The Board of Directors is composed of founders, international investors specialised in biotech and independent executives from top pharma companies.
ObsEva also benefits from the expertise of an independent & international advisory team (Scientific Advisory Board) composed of high level, academic specialists in OB-GYN and reproductive medicine.
ObsEva is advancing a robust pipeline of novel, oral, late-stage compounds to treat women’s reproductive health conditions
from conception to birth.
3 novel compounds, 3 Phase 2 programs
Partnering is important to fast developing specialty biopharmaceutical companies. ObsEva is building its clinical product portfolio around multiple collaborations demonstrating the company’s ability to manage close collaborations with integrity, transparency and commitment.
How to contact ObsEva ?» contact us